Adaptive Trial Design AI in Clinical Trials Alzheimer's Disease Analysis Animal Testing Alternatives Article Artificial Intelligence in Clinical Trials Clinical Research Clinical Trial Design Clinical Trial Diversity Clinical Trial Innovation Clinical Trial Payments Clinical Trial Quality Clinical Trials CNS Trials Conference Coverage Data Analysis Data Management DCT Decentralized Clinical Trials DHT Digital Health Technologies eClinical Tech News EMA PRAC EU regulatory landscape Executive Interviews FDA FDA Guidance FDA Regulatory Compliance FDA Regulatory Strategy Immuno-Oncology Ketamine Therapy News Obesity Trials Opinion Patient Stratification Pfizer Precision Oncology Psychedelics Rare Disease RBQM Real-World Evidence RWD RWE Treatment-Resistant Depression
Pull up FDA’s 2024 draft guidance on the regulation of human gene therapy products and read the agency’s framing language. Then read the Supreme Court’s 2024 opinion in Loper Bright Enterprises v. Raimondo. The collision is not subtle. For four decades, agencies like the FDA built regulatory authority over emerging biotechnology not by explicit congressional mandate but by the accumulated deference that courts extended to agency expertise under Chevron U.S.A., Inc. v. Natural Resources Defense Council. Loper Bright ended that. Courts must now independently interpret statutory ambiguity. And synthetic biology — a field that routinely produces organisms, materials, and therapeutics that no statute from 1938 or 1997 anticipated — sits at the center of a regulatory vacuum that is widening every month.
Three signals, running across different regulatory domains simultaneously, point to a pattern the industry has not yet named: Deference Erosion, and the downstream collapse of FDA’s ability to extend its existing frameworks to cover technologies that outpace the statutory text those frameworks were built on.
The first signal came from the Supreme Court itself. In Loper Bright Enterprises v. Raimondo, decided in 2024, a 6-3 majority overruled Chevron deference, holding that courts must exercise independent judgment when interpreting ambiguous statutory text rather than deferring to agency interpretations. Chief Justice Roberts, writing for the majority, stated explicitly that agencies lack special authority to resolve statutory ambiguities — that interpretive power belongs to courts. For FDA, which has long governed categories of products through broad readings of terms like “drug,” “device,” and “biological product,” this recalibration is not theoretical. It is existential for entire product categories.
Synthetic biology generates exactly the kind of product that strains statutory categories. A living therapeutic that rewires cellular metabolism — is it a drug? A device? A biological product? A combination? FDA has historically answered that question through guidance documents, advisory committee frameworks, and informal designation letters, all of which rested on the premise that courts would defer to agency expertise when the statute was silent or ambiguous. That premise is gone. Any sponsor that receives a designation for a synthetic biology product and then faces a legal challenge from a competitor, a payer, or a state regulator now must defend that designation in front of a court exercising independent statutory judgment. The guidance document that anchored the designation carries no special weight.
That shift alone would be significant. But it coincides with a second, operationally distinct signal that makes the problem structurally acute.
Open the Federal Register to FDA’s 2023 framework for RWE in regulatory decision-making. The framework, built on the agency’s authority under the 21st Century Cures Act, describes conditions under which real-world data — including data from digital health technologies and decentralized elements — can support labeling decisions. Now apply that framework to a synthetic biology clinical program: a Phase 2 trial of a programmable bacterial therapeutic where the primary endpoint involves microbiome modulation measured through genomic sequencing outputs that have no validated predicate. There is no CDISC standard for that endpoint. There is no FDA guidance on what constitutes an adequate and well-controlled study for a living therapeutic whose mechanism of action changes dynamically within the patient. The RWE framework does not cover it because no one wrote it to cover it.
This is the second signal: FDA’s existing evidence frameworks, including the RWE guidance and the adaptive trial design guidance finalized in 2019, were written for a product universe that synthetic biology has already left behind. Under Chevron, FDA could have extended those frameworks through interpretive guidance and expected courts to defer. Under Loper Bright, any sponsor who structures a trial around a novel FDA interpretation of an existing evidence framework is building on ground that a court can now reject entirely, with no deference owed to the agency’s reading.
Consider what that means in practice for a sponsor running a first-in-class engineered cell therapy trial. FDA’s Center for Biologics Evaluation and Research issued guidance in 2022 covering considerations for gene therapy development — but that document does not address programmable synthetic organisms that self-replicate or adapt post-administration. If CBER designates such a product as a biological under the Public Health Service Act and a challenger contests that classification in federal court, the court owes FDA’s statutory interpretation nothing. The agency must now win on the text, not on its expertise.
That is a fundamentally different negotiation than the one the industry has been conducting for thirty years.
The third signal is quieter but may be the most consequential for clinical operations specifically: FDA’s budget environment is deteriorating at the same moment the agency needs to build new statutory-text-grounded frameworks for product categories that have no legislative home. DOGE-driven agency reductions in 2025 and into 2026 have reduced FDA staffing capacity across review divisions. Building a new regulatory architecture for synthetic biology — one robust enough to survive independent judicial review rather than relying on deference — requires legal depth, scientific drafting resources, and congressional engagement that a budget-constrained agency cannot realistically deliver on the timelines that the field demands.
The counterintuitive read here is not that Loper Bright will necessarily produce adverse court rulings against FDA on synthetic biology. It may not, at least not immediately. The more dangerous near-term consequence is regulatory hesitancy: an agency uncertain of its own legal ground that defaults to the narrowest possible interpretations, the longest possible review timelines, and the most conservative designation decisions — not because the science demands it, but because every novel interpretation is now a litigation target without the protective cushion of deference.
For sponsors, the operational implication is direct. Any IND strategy for a synthetic biology program that relies on FDA’s willingness to apply an existing framework by analogy — “this is like a gene therapy, therefore we apply CBER’s 2022 gene therapy guidance” — now carries legal risk that did not exist before 2024. That risk belongs on the protocol development checklist alongside GCP compliance and IRB submission timelines.
For CROs, the implication is that endpoint selection and data collection methodology for synthetic biology trials must be built to survive not just regulatory review but independent judicial scrutiny. If a court can second-guess whether a bacterial therapeutic is a “drug” under the Federal Food, Drug, and Cosmetic Act, that court can also scrutinize whether the evidence standard FDA applied to approve it was authorized by statute. Every trial design decision downstream of a contested product designation becomes a liability.
Technology vendors in the eClinical space face a less obvious but equally real exposure. The companies building eCOA platforms, wearable data pipelines, and AI-powered endpoint analysis tools for synthetic biology programs have been designing to FDA guidance specifications — specifications whose legal durability is now uncertain. A platform validated against FDA’s existing digital health technology framework, which itself depends on agency interpretations of what constitutes reliable evidence, is a platform whose evidentiary basis a court can now independently reassess. Vendors who have not begun mapping their validation frameworks to the underlying statutory text — rather than the guidance layered on top of it — are behind.
The FDA’s posture here is understandable: the agency is navigating a post-Chevron world without new statutory authority and with fewer resources to build the legal infrastructure that post-Chevron governance requires. But understandable does not mean adequate. The 21st Century Cures Act gave FDA important tools for evidence modernization, but it did not anticipate programmable living therapeutics, self-replicating synthetic organisms, or the categories of synthetic biology products currently in Phase 1 development at companies including Ginkgo Bioworks and Synlogic. Congress has not returned to update the statutory text. FDA cannot write its way to safety through guidance alone, and Loper Bright has removed the safety net that once made guidance sufficient.
In 12 to 18 months, the first major judicial challenge to an FDA synthetic biology product designation will reach a federal circuit court exercising post-Loper Bright independent review. When it does, the trial program sitting underneath that designation — with its IND, its enrolled patients, its endpoint framework, its RWE strategy — will face a disruption that no protocol amendment can cure. The sponsors who will survive that moment are the ones who stopped treating FDA guidance as a legal foundation and started building directly on statutory text. The ones who did not will discover, at the worst possible time, that the framework they built their clinical program on was borrowed authority — and it has expired.
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.
Start typing and press Enter to search
